NEVVI Medicare utilization intelligence
or

← back

Provider profile

WAHEED, SALMAN M.D.

Hematology-Oncology · NPI 1104146505 · JOLIET, IL

1
Groups
55
Codes · 2024
76,614
Disclosed services

WAHEED, SALMAN is a Hematology-Oncology in JOLIET, IL, a member of 1 medical group, who billed 55 distinct codes to Medicare Part B in 2024.

Groups: DUPAGE MEDICAL GROUP LTD (GLEN ELLYN, IL)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

76,614
disclosed services
55
codes billed to Medicare Part B
Prior year · CY2023 39,464 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J3262 Injection, tocilizumab, 1 mg
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J3380 Injection, vedolizumab, intravenous, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
J1745 Injection, infliximab, excludes biosimilar, 10 mg
J0897 Injection, denosumab, 1 mg
36415 Insertion of needle into vein for collection of blood sample
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J1100 Injection, dexamethasone sodium phosphate, 1 mg
80053 Blood test, comprehensive group of blood chemicals
J2469 Injection, palonosetron hcl, 25 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J2405 Injection, ondansetron hydrochloride, per 1 mg
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
J3489 Injection, zoledronic acid, 1 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J9045 Injection, carboplatin, 50 mg
83615 Lactate dehydrogenase (enzyme) level
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
96415 Administration of chemotherapy into vein, each additional hour
82607 Cyanocobalamin (vitamin b-12) level
82746 Folic acid level, serum
96372 Injection of drug or substance under skin or into muscle
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J1200 Injection, diphenhydramine hcl, up to 50 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96417 Administration of additional new drug or substance into vein, 1 hour or less
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
85007 Microscopic examination for white blood cells with manual cell count
82232 Beta-2 microglobulin (protein) level
82378 Carcinoembryonic antigen (cea) protein level
96523 Irrigation of implanted venous access drug delivery device
J7030 Infusion, normal saline solution , 1000 cc
96360 Infusion into a vein for hydration, 31-60 minutes
83735 Magnesium level
83010 Haptoglobin (serum protein) level
84100 Phosphate level
86038 Screening test for autoimmune disorder
87389 Detection test by immunoassay technique for hiv-1 antigen and hiv-1 and hiv-2 antibodies
96411 Administration of additional new drug or substance into vein using push technique
85045 Red blood count, automated test
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
84443 Blood test, thyroid stimulating hormone (tsh)
85049 Platelet count, automated test

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.